Kymera in the News

Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.

Featured Perspectives

Headshot of Karen Weisbach
March 31, 2023
Driving Culture Through Values
Karen Weisbach, PHR, Head of People + Culture
Headshot of Juliet Williams
March 1, 2023
Living Our Core Values – Pioneer: Breaking new ground with a powerful new modality
Juliet Williams, PhD, Head of Research
Headshot of Brian Albarran
April 21, 2023
Small Molecules, Big Impact: Expanding the Universe of Targets
Brian Albarran, PhD, Senior Vice President, Head of Corporate Strategy
Showing 27 news results
May 23, 2024

PharmaLeaders: Upending Traditional Wisdom at DDW, an Interview with Nello Mainolfi, PhD

PharmaLeaders had the chance to discuss Kymera’s exciting progress with Founder, President and CEO, Nello Mainolfi, Ph.D.

Read More
March 18, 2024

Boston Business Journal: Biotech Upgrades to New Watertown Digs with Triple the Space

The Boston Business Journal highlighted Kymera’s recent move to enable the expansion of our innovative R&D capabilities and support our growing team’s vibrant on-site presence as we work toward delivering life-changing medicines to patients.

Read More
February 29, 2024

Scrip: Kymera Puts Emphasis On Immunology In New Growth Phase

CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.

Read More
January 4, 2024

Endpoints News: Kymera doubles down on protein degraders for immunology, chasing Dupixent and Sotyktu

Looking to further expand the reach of protein degraders beyond cancer, Kymera Therapeutics revealed two new programs Thursday morning that it hopes will compete with some of the hottest immunology drugs on the market.

Read More
December 26, 2023

Genetic Engineering & Biotechnology News: Up-to-$2B Sanofi Collaboration Pays Off for Kymera

Through a pair of recent clinical milestones, Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi to develop first-in-class targeted protein degradation (TPD) therapies for patients with immune-inflammatory diseases.

Read More
December 11, 2023

BioCentury: Building on dermatology’s recent success

Once cast off by most pharmas and investors, dermatology drug development is experiencing a renaissance. A standout commercial success has put atopic dermatitis on the map. Each new psoriasis therapy is extending efficacy. And emerging drug classes are promising to expand the pool of responders, both within dermatology’s major indications and into new ones.

Read More
December 4, 2023

Nature Reviews Drug Discovery: PROTAC in clinic for autoimmune skin disease

The kinase IRAK4 is a crucial regulator of signalling pathways that control innate immunity. Inhibitors of its kinase activity have been developed for autoimmune diseases but have not shown strong efficacy. Now, in Nature Medicine, Ackerman et al. describe an IRAK4 protein degrader and report encouraging preliminary results in patients with chronic inflammatory skin diseases.

Read More
November 29, 2023

Boston Globe: Top Places to Work in Massachusetts 2023

Nearly 76,000 workers at 347 companies responded to the survey questions rating their employers on leadership, values, training, benefits, and other metrics. The rankings are broken down into four size categories: small (50-99 employees); medium (100-249); large (250-999); and largest (1,000 or more).

Read More
November 28, 2023

Drug Hunter: KT-474 Brings IRAK4 Back: The First Clinically Active Bifunctional Degrader Outside Oncology

Kymera’s KT-474 is the first oral degrader to demonstrate activity in clinical trials outside cancer. Sanofi recently started a Ph. II trial with the molecule in AD, restoring life to IRAK4 as an immunology target.

Read More
November 20, 2023

Dermatology News: KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study

Kymera Therapeutics recently shared promising results from the phase 1 clinical trial of its lead program, KT-474, marking a significant milestone in the field of targeted protein degradation (TPD).

Read More


Featured Presentations & Publications

December 10, 2023
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Hematology (ASH) Annual Meeting and Exposition 2024
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.